NKX2-3 and B-cell non-Hodgkin lymphoma: Our study reveals NKX2-3 as a bona fide oncogenic driver in marginal-zone B-cell lymphomas, and provides an experimental mouse model to study the functional biology and therapy of this lymphoma entity.